"Risk reduction as a public health strategy to eradicate cigarette smoking", is going to be discussed in Rome on Wednesday 9th November as part of a conference promoted by Motor Health in the "Sala Cristallo" of Hotel Nazionale in Piazza Montecitorio.
Harm Reduction strategies were the subject of a speech by prof. Polosa during the National Congress of the Italian Society of Internal Medicine. Focus of this year edition, the management of…
CoEHAR Director Giovanni Li Volti and the co-project leader of the Replica project Massimo Caruso have been invited to be part of the 5th Scientific Summit on Harm Reduction in Athens to deliver a presentation on the latest results obtained by the Replica project and their implication for public health.
The Replica project team activity and the results of the studies on the reduced cytotoxicity and inflammation induced by cigarette smoke and ENDS aerosol will be presented during the XVI edition of the Congress of the Italian Federation of Life Sciences (FISV), which represents over 10.0000 Italian scientists and which will take place from 14 to 16 September 2022 in Naples
The meeting “75th Tobacco Science Research Conference” is an incredible opportunity for researchers and professionals to discuss, analyze and deepen the latest news on tobacco harm reduction strategies, including the necessary steps to develop the scientific activity and the engagement of the sector
The 5th Scientific Summit on Tobacco Harm Reduction: Novel products, Research & Policy, is organised by SCOHRE, the International Association on Smoking Control & Harm Reduction, and will be held on…
CoEHAR researchers, involved in the Replica project, have shown that switching to electronic cigarettes and heated tobacco products reduce the vascular damage and the onset of diseases such as arteriosclerosis.
The In Silico Science research team conducted a series of robust and exhaustive systematic reviews to bring forward the best available evidence on the health effects of e-cigarettes on human health developing data for clinicians
The use of e-cigarette among teenagers in the United States is considered a significant public health problem. A close look at federal data now show that the number of young e-cigarette users has markedly declined to below epidemic levels since its peak in 2019.
A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus